Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Ann Allergy Asthma Immunol. 2011 Feb 26;106(4):308–315. doi: 10.1016/j.anai.2011.01.015

Table 2a.

Indoor coarse PM concentrations and asthma morbidity by atopic status: bivariate models*

Non-atopic coarse Atopic coarse

IRR 95% CI p-value IRR 95% CI p-value
Cough, wheezing, chest tightness 1.06 (1.0, 1.13) 0.06 1.02 (0.92, 1.13) 0.68
Slow down 1.07 (1.0, 1.13) 0.05 1.14 (1.04, 1.25) <0.01
Symptoms with running 0.73 (0.56, 0.90) <0.01 1.12 (1.01, 1.23) 0.02
Nocturnal symptoms 1.08 (1.02, 1.15) 0.01 1.03 (0.93, 1.14) 0.55
Limited speech 1.11 (1.04, 1.18) <0.01 1.14 (0.99, 1.30) 0.07
Beta Agonist use 1.07 (1.01, 1.13) 0.02 1.06 (0.96, 1.15) 0.24
*

Incidence rate ratios (IRR) are presented per 10 μg/m3 increase in PM concentration.

Models were adjusted for age, race, gender, parent education, season, indoor PM2.5, outdoor PM2.5, and outdoor PM2.5–10